

Review

Open Access



“Not much room for mushrooms” in the heart: knowns and unknowns of fungal infective endocarditis

Wilhelm Mistiaen^{1,2}

¹Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp 2610, Belgium.

²Department Health & Sciences, Artesis-Plantijn University of Applied Sciences, Antwerp 2000, Belgium.

Correspondence to: Prof. Wilhelm Mistiaen, Faculty of Medicine & Health Sciences, University of Antwerp, Campus Drie Eiken, Building R, 3rd Floor, Antwerp 2610, Belgium. E-mail: wilhelm.mistiaen@uantwerpen.be

How to cite this article: Mistiaen W. “Not much room for mushrooms” in the heart: knowns and unknowns of fungal infective endocarditis. *Vessel Plus* 2024;8:1. <https://dx.doi.org/10.20517/2574-1209.2023.77>

Received: 28 Jun 2023 **First Decision:** 17 Nov 2023 **Revised:** 19 Dec 2023 **Accepted:** 3 Jan 2024 **Published:** 10 Jan 2024

Academic Editors: Carlos A. Mestres, Ugolino Livi **Copy Editor:** Fangling Lan **Production Editor:** Fangling Lan

Abstract

Fungal infective endocarditis is a rare but highly lethal condition. Its diagnosis is often delayed due to nonspecific symptoms, inconclusive medical imaging, and negative blood cultures. Recent reviews of cases and series over the last 5 years indicate that the condition remains rare and lethal. If fungi are identified as the causative agents in more than 5% of patient cases with infective endocarditis, it is likely that risk factors such as immune suppression or cardiac implants are probably involved. A series derived from recent case reports indicates that *Candida* and *Aspergillus* are still the main causative infectious agents, with *C. parapsilosis* on the rise. From these cases, diagnostic clues (frequent embolisms, ophthalmic involvement, large, mobile and friable vegetation, non-valvular cardiac manifestations) are pointing towards fungal IE. These reports, however, are not standardized and a publication bias towards rare microorganisms or towards a favorable outcome might exist. Complications might be underreported, and important data such as diagnostic delay are absent or difficult to retrieve. Pharmacologic treatment is not fully standardized. Knowledge of resistant strains in this respect is important. Statistical analysis for the effect of complications and treatment modalities on outcome shows that any result should be treated cautiously. The current series is by no means a valid substitute for a well-designed series of fungal endocarditis. However, the better outcome with *Candida* and patients treated with surgery confirm earlier results. An international multicentric standardized registry of cases with fungal endocarditis in order to improve the outcome of this disease is highly needed. The effect of diagnostic delay on outcome remains elusive and should be resolved.

Keywords: Endocarditis, diagnosis, complication, management, mortality



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



INTRODUCTION

Infective endocarditis (IE) has a low incidence but a high mortality and complication rate^[1]. The available series studying IE are usually small and randomized controlled trials are absent. IE is typically observed in patients with pre-existent valve disease, valve prostheses, and specific risk factors such as an immune compromised state or a colorectal neoplasm serving as port-of-entry^[2]. Fungal IE is even more uncommon compared to bacterial IE. Often, blood cultures are negative^[1,3], but echocardiographic changes might offer some clues in fungal IE^[4]. Its incidence, however, is expected to rise because of the increase in cardiac implants and the prolonged use of intravenous catheters and antibiotics^[3]. The two most common microorganisms in fungal IE are *Candida* and *Aspergillus*. *Candida* IE carries an early mortality rate of almost 50%. Long-term data are scarce^[5]. *Aspergillus* accounts for about a quarter of fungal IE, is difficult to diagnose, has mostly a negative blood culture, and is therefore a risk for a delayed diagnosis. Cardiac surgery is a necessary part of the treatment. Mortality after the procedure is also high^[3] and the diagnosis is often post-mortem^[6]. Other fungal IE such as *Trichosporon*, *Histoplasma*, *Cryptococcus*^[7-9], and other rare species should also be held into account in patients with risk factors. Since this is an evolving field, the research questions focus on the last 5 years. These are

- (1) What is the rate of fungal IE in published series?
- (2) What organisms have been identified in the cases published?
- (3) What are the short and long-term outcomes of fungal IE?
- (4) Are these cases sufficiently documented with respect to potential predictors for outcome, especially with respect to delayed diagnosis?
- (5) Are there recently developed management policies for fungal IE?

METHODS

This is a systematic review based on the Web of Science source. The search terms “endocarditis AND fung*” were used. Using simple search terms limits the risk of missing important manuscripts. A search of the last 5 years resulted in 1,741 hits, with 1,601 articles. Exclusion criteria were articles concerning pharmacologic and environmental issues. Reviews, editorials, and manuscripts describing entirely pediatric series were excluded. From the remaining 708 manuscripts, only full articles with explicit analysis of fungal endocarditis ($n = 30$) were included. Articles referring to “other microorganisms” and “negative culture” were too vague to consider and were also excluded. In a second round, 86 reports describing 91 cases were studied for known risk factors, estimated time between first symptoms and diagnosis being > 30 days, emboli and especially stroke, heart failure, cardiac abscesses, acute renal injury, type of fungus, antifungal treatment, surgical treatment, surgery indicated but deemed too risky, hospital mortality, long-term survival. The effect of risk factors on hospital mortality was analyzed with a chi-square analysis and significant factors were entered in a multivariate logistic regression, to identify independent predictors. One- and three-year survival rates were estimated by a Kaplan-Meier analysis.

RESULTS

Rate of fungal microorganisms in the included series of infective endocarditis

The prevalence of fungal IE in large series is summarized in [Table 1](#). Thirty series could be identified. There is a large variation in the rates of fungal IE, which ranges from less than 1%^[10-16], between 1% and 2%^[17-29], between 2% and 5%^[30-34], to over 5%^[35-39]. The latter series included patients with an immune compromised

Table 1. The incidence (rate) of fungal infection in the included series of endocarditis

Refs.	n/N	% fungi	Time span	Comment
Acibuca <i>et al.</i> 2021 ^[10]	1/139	0.7	2009-2019	Descriptive series
Berisha <i>et al.</i> 2022 ^[17]	14/749	1.9	2008-2020	PVE series
Cahill <i>et al.</i> 2019 ^[12]	6/706	0.8	2008-2016	Congenital heart disease
Vallejo Camazón <i>et al.</i> 2019 ^[19]	5/271	1.9	2003-2018	Surgery vs. no surgery
Cao <i>et al.</i> 2020 ^[39]	7/62	11.3	1997-2018	PVE, stroke
Chen <i>et al.</i> 2020 ^[35]	16/678	2.4	2015-2019	NLR as predictor
Chuang <i>et al.</i> 2019 ^[36]	1/70	1.4	2008-2014	Transplant
Elad <i>et al.</i> 2020 ^[20]	1/92	1.1	2013-2016	Effect IE-team: pre : post
Fosbøl <i>et al.</i> 2019 ^[18]	6/422 12/584	1.4 2.9	2008-2012	Vegetation size: small : large
Geirsson <i>et al.</i> 2020 ^[30]	361/11,756 351/23,149	3.1 1.5	2011-2018	STS-IV drug pts STS-other patients
Gröning <i>et al.</i> 2019 ^[37]	2/23	8.7	NS	RVOT repair
Guo <i>et al.</i> 2021 ^[31]	4/124 15/414	3.2 3.6	1997-2017	Hemodialysis: yes : no
Gutierrez-Villanueva <i>et al.</i> 2021 ^[22]	6/27 8/407 39/3,242	22.2 2.0 1.2	2008-2017	Mural IE Device IE Valve IE
Houhamdi-Hammou <i>et al.</i> 2021 ^[33]	3/16	18.8	2011-2015	BCNE
Jeronimo <i>et al.</i> 2022 ^[11]	18/1,655	1.6	1998-2020	<i>Candida</i>
Jia <i>et al.</i> 2019 ^[21]	3/161	1.9	2007-2016	Evaluate diagnostic criteria
Martínez-Sellés <i>et al.</i> 2021 ^[26]	82/4,696 7/4,696 3/18	1.7 0.1 16.7	2008-2019	<i>Candida</i> (all patients) Other fungi (all patients) Other fungi tHTx patients)
Mir <i>et al.</i> 2022 ^[27]	1122/255,838 250/16,670	0.5 1.7	NS	All IE nationwide Fatal IE nationwide
Okura <i>et al.</i> 2021 ^[28]	0/59 3/179	0.0 1.7	1998-2008 2008-2019	Pre infect dept consult Post infect dept consult
Pasupula <i>et al.</i> 2019 ^[29]	683/48,500	1.4	2010-2014	Fungal IE constant
Polewczyk <i>et al.</i> 2021 ^[13]	8/1,241	0.6	2006-2017	CIED
Ponnambath <i>et al.</i> 2021 ^[38]	13/47	27.7	2010-2020	PVE
Pyo <i>et al.</i> 2021 ^[32]	3/56 4/213	5.4 1.9	2013-2019	PVE NVE
Ragnarsson <i>et al.</i> 2021 ^[14]	5/864 5/806 2/516	0.6 0.6 0.4	2006-2017	< 65 year age class 65-79 year age class > 80 year age class
Ramanathan <i>et al.</i> 2021 ^[34]	13/296 4/215	4.4 1.9	2013-2016	Not invasive at surgery Invasive at surgery
Rodger <i>et al.</i> 2019 ^[15]	1/212 5/68	0.5 7.4	2007-2017	First IE in IV drug Recurrent IE in IV drug
Salsano <i>et al.</i> 2019 ^[23]	3/191	1.6	2000-2019	Surgery, BCNE
Sousa <i>et al.</i> 2021 ^[16]	10/7,574	0.1	2010-2018	Trends
Sunder <i>et al.</i> 2019 ^[24]	46/4,003	1.3	2011-2011	BCNE excluded
Tahon <i>et al.</i> 2021 ^[25]	3/270 1/10	1.1 10.0	2000-2007	First IE Early recurrent IE

BCNE: Blood culture negative endocarditis; CIED: cardiac implanted device IE; HTX: heart transplantation; IE: infective endocarditis; IV: intravenous; NLR: neutrophil-lymphocyte ratio; NS: not stated; NVE: native valve endocarditis; PVE: prosthetic valve endocarditis; STS: the society of thoracic surgeons database.

state such as after transplantation^[36] or with prosthetic valves^[38,39]. Most authors group all fungal IE in one category^[13,15-20,29,30,32,34-36]; some only mention *Candida* ssp^[10,15,22-24,28], or specify the *Candida* subspecies^[11,21,37,39], or group *Candida* together with *Aspergillus*^[25] or focus on one specific agent such as *Malassezia*^[33].

Most series are descriptive; some compare subgroups of patients, such as the effect of the installation of an endocarditis team^[20,28], size of vegetation over vs. under 10mm, and IV drug users vs. non-drug users^[18,30]. Other authors studied the effect of hemodialysis^[51], certain subtypes of IE (valvular vs. mural vs. electronic device IE), the effect of immune suppression in heart transplant patients, fatal vs. non-fatal cases^[26,27], prosthetic vs. native valve endocarditis, age classes, invasiveness of IE at surgery^[14,32,34], and first vs. recurrent IE^[14].

Case reports

In 86 reports, 91 cases of definitive fungal IE were described. These reports involved fifteen cases with *Candida parapsilosis*^[40-54], seven cases with *C. albicans*^[55-61], three cases with *C. tropicalis*^[62-64], eight other species with *Candida*^[65-72], eight cases with *Candida* with a bacterium^[73-80], ten cases with *Aspergillus fumigatus*^[81-90], nine cases with other species of *Aspergillus*^[91-99], four cases with *Cryptococcus*^[100-103], four cases with *Histoplasma*^[104-107], four cases of *Trichosporon*^[108-111], two cases of *Fusarium*^[112,113], one case of *Scediosporium*^[114], *Chaetomium*^[115], *Malassezia*^[116], *Rhizomucor*^[117], *Exophiala*^[118], *Purpureocillium*^[119], *Sarocladium*^[120], *Paecilomyces*^[121], *Cunninghamella*^[122], *Geotrichum*^[123], *Bipolaris*^[124] and *Volvariella*^[125]. In this case series, 74 patients were males. The mean age was 57+/-17.5 years. Thirty-six patients had a prior implanted valve prosthesis, 16 patients had other implants, of which 7 were pacemakers, 25 patients were immune compromised because of prior transplant, or steroid treatment for auto-immune disease, and 11 patients were IV drug users. Symptoms of fungal IE were usually insidious, non-specific, and heterogenous, including asthenia, feeling of weakness, anorexia, fever, headache and weight loss. In 30 cases, there were sudden embolic phenomena such as stroke or limb ischemia. Symptoms and signs suggestive of congestive heart failure were present in 14 cases, but distinguishing these from pulmonary infections was not always straightforward.

A blood culture was almost universally performed, but these were not always positive [Table 2]. Often, a culture or a histologic examination of a valve specimen (native or prosthetic) or thrombus after surgical treatment was necessary. This additional examination was performed for most patients as further identification of the involved infective microorganisms. In some cases, a culture was performed after bronchoalveolar lavage to detect *Aspergillus*^[81,89,93], *Fusarium*^[113], *Rhizomucor*^[117], and *Cunninghamella*^[122]. Cerebrospinal fluid was examined in two patients with a *Cryptococcus* infection^[100,102] and in one with a *Volvariella* endocarditis^[125]. A urine examination was performed on three patients infected with *Histoplasma*^[104,106,107]. Skin lesions and skin appendages were examined in cases with *Histoplasma*^[105], *Trichosporon*^[111], and *Fusarium*^[112]. Table 2 shows the most common fungal agents, mostly *Candida* ssp. and *Aspergillus* ssp., followed by *Cryptococcus*, *Histoplasma*, and *Trichosporon*. The table lists only the most common subspecies, the reference, the number identified in the case series, the number with positive blood culture, and the rate of delay of more than 30 days. The rate of positive blood cultures for *Candida* was 32/44 or almost 75%, while for *Aspergillus*, this rate was much lower (4/23). A delay in diagnosis of 30 or more days was documented in 33 cases; in 24 other patients, there was no report of delay. In spite of more negative blood cultures in *Aspergillus*, compared to *Candida*, the delay in diagnosis for *Aspergillus* IE was not higher. In patients with emboli, the delay to diagnosis was more often shorter, but this was not significant (1/7 vs. 21/48, $P = 0.223$).

In many cases with negative cultures or difficulties in identifying the infecting fungal microorganism, beta-D-glucan testing was performed. This was needed in a minority of *Candida* infections^[51,54,55] but more often in *Aspergillus*^[81,84,87,90,92,96] and certain other fungal species^[101,106,107,118,120-124]. Detection for the presence of galactomannan was also performed in IE by *Aspergillus*^[85,89,92,93] and other uncommon species^[112-114,120,121,125]. Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) has been developed to sequence proteins, map biomolecules in tissues, identify microorganisms, and analyze

Table 2. Fungi in case reports

Microbial agent	Reference	Number	Positive culture	Delay > 30 days
<i>Candida</i> (all)	[40-80]	44	32	13/30 (43.3%)
- <i>C. parapsilosis</i>		19	16	
- <i>C. albicans</i>		10	6	
- <i>C. tropicalis</i>		4	3	
<i>Aspergillus</i> (all)	[81-99]	23	4	6/19 (31.6%)
- <i>A. fumigatus</i>		14	4	
<i>Cryptococcus</i>	[100-103]	4	4	1/3 (33.3%)
<i>Histoplasma</i>	[104-107]	4	1	3/4 (75.0%)
<i>Trichosporon</i>	[104-107]	4	2	2/4 (50.0%)

several biochemical assays in a short time. It was used in five patients with *Candida* infection^[52,63,66,68,72], and in 5 patients with other species^[109,111,113-116], but not with *Aspergillus*. Quantitative polymerase chain reaction (qPCR) with genetic sequencing was performed in only one patient with *Candida* infection^[71], three with *Aspergillus* infection^[81,92,95], and for several other microorganisms^[112,117,122,124,125]. To document and, if necessary, treat ocular involvement, an ophthalmic examination was performed in ten patients with *Candida* infection^[45,49,52,56,57,59,62,63,76,78], five patients with *Aspergillus*^[81,87,88,93,97], and three patients with other species^[113,114,124].

Transthoracic (TTE) and transesophageal (TEE) echocardiography were almost universally performed in the included case reports since this imaging modality is a cornerstone in the diagnosis of native and prosthetic infective endocarditis. Most of the cases underwent computer tomographic (CT) imaging and MRI of the brain, thorax, abdomen, and pelvis, as well as CT-angiography, encompassing almost all infective species involved. A positron emission tomography or PET/CT scan was performed in order to confirm or exclude other septic foci for various fungal species such as *Candida*^[50,60,69,80], *Aspergillus*^[96,97], and other infective agents^[104,119].

IE was left-sided in 71, right-sided in 14 and on both sides in 6 cases. Reporting of the pharmacologic treatment for fungal IE was not standardized. Amphotericin was used in 63 cases, Azoles in 55 cases, Echinocandins in 41 cases, and Flucytosine in 15 cases. Monotherapy was used in 25 cases, mostly with amphotericin. There was a switch in treatment in 25 patients because of lack of effect. Valve surgery and removal of fungal balls were performed in 55 cases. In 10 patients, an electronic cardiac device was removed. Surgery was indicated in another 11 cases, but was not performed because of the poor condition of the patients. The need for emergent surgery (< 24 h) is almost nowhere described. Complications are not described in a uniform way and are therefore probably incomplete. Most frequently, thromboembolism affects the brain, liver, spleen, kidneys, and limbs. A cardiac abscess was documented in 14 cases, but heart failure was rarely reported. The renal condition was mentioned in only 35 reports: it remained unaffected in 8 cases, while in 27 cases, there was impaired renal function. Twenty-nine patients (31.9%) died within the hospital. Long-term survival was recorded in 56 patients, but only 27 of them had a follow-up duration of 12 months or more. A chi-square analysis showed that hospital mortality was significantly lower with *Candida* vs. non-*Candida* (6/42 vs. 23/49, $P < 0.001$), while *Aspergillus* vs. non-*Aspergillus* showed significantly higher mortality (11/23 vs. 18/70 with $P = 0.047$). Left-sided IE was also unfavorable (26/73 vs. 2/18, $P = 0.044$). Valve surgery was protective against mortality (11/55 vs. 15/34, $P = 0.015$). However, patients deemed too sick to undergo cardiac surgery fared not significantly worse (5/12 vs. 3/4, $P = 0.248$), but numbers were low and might be incomplete. Other factors such as gender, antifungal drug type, IV drug use, other cardiac implants or central venous lines, immune suppression, emboli, cardiac abscesses, a negative blood culture, and delay of diagnosis of > 30 days showed no significant effect. This window was chosen somewhat

arbitrarily^[76]. Remarkably, patients with prior cardiac surgery did better (7/36 vs. 23/55, $P = 0.036$), although they had no less delay of diagnosis, nor did they undergo more cardiac surgery for the current episode of IE. Multivariate logistic regression analysis showed a protective effect of cardiac surgery (odds ratio 0.15, $P = 0.001$), and patients with *Candida* IE (odds ratio 0.15, $P = 0.004$) also fared better. The effect of prior cardiac surgery lost its significance for mortality. Data on long-term survival are notably incomplete due to the limited data available in the case reports. Observed one-year survival was 83.0+/-5.6% (26 patients reported) and 3-year survival was 73.7+/-10.0% (8 patients reported). A delay in diagnosis of > 30 days showed a trend for lower 1-year survival: 74.2+/-10.1% vs. 95.0+/-4.9% ($P = 0.079$). None of the other factors had an effect on long-term survival.

DISCUSSION

The designs and the patient sample sizes of the included series [Table 1] varied considerably. Fungal IE is mostly between 1 and 4%, while the most common infectious agents are *Staphylococci*, *Streptococci*, and *Enterococci*. Only in series with known risk factors such as valve prosthesis implant, immune compromised states such after transplantation, IV drug use, or special manifestations such as mural IE, the rate of fungal IE exceeds 5%. These sample sizes, however, are much smaller, indicating that it is difficult to collect large series with fungal IE. Furthermore, the majority of the included series group all fungal infective agents in one category as “fungal” or as “*Candida*” without further specification. *Aspergillus* is mentioned only once. Nevertheless, from prior reports^[1] and current cases, it can be derived that *Candida* and *Aspergillus* are dominant. However, the currently included case reports are by no means a substitute for a properly designed patient series since there is no uniformity with respect to patient inclusion, diagnostic work-up, or treatment. As a result, many complications may be underreported and there might be a publication bias concerning the uniqueness of a case or an unexpected outcome. This could be the reason for the surprisingly low mortality rate of the current case series, particularly those with prosthetic valve endocarditis (PVE)^[1,53,58,80,89,103,107]. However, in line with prior observations, *Candida* species, with a reported 40%-60% rate^[44,52,57,60,69,62,94,96,123,126], is the most frequently reported infectious agent in the current case series. *Candida parapsilosis* is the most frequent non-albicans fungus causing IE¹ and exhibits an escalating trend^[11,53]. Corresponding with prior reports, the outcomes associated with *Candida*-related IE in the current case series are more favorable and cardiac surgery protects against early death. Following *Candida*, *Aspergillus* emerges as the second most significant fungus, which accounts for about 25% of fungal IE cases^[81,88,89,95].

Signs and symptoms of fungal IE

Although signs and symptoms can vary significantly and are non-specific, fungal IE has some peculiarities. First, emboli are more frequent in fungal IE compared to bacterial IE, and their occurrence might offer a clue. These emboli can be related to large fungal vegetations, which are friable and highly mobile^[43,52,56,57,76,78,90,93,95,98,99]. Stroke was documented in 29 of the included cases, while splenic, renal, pulmonary, or peripheral embolism were documented in 20 cases. Endophthalmitis and ophthalmic emboli should be reasons for an ophthalmologic examination^[49,50,57,71,78,87,88,97,114]. Second, prior valve implantation and electronic cardiac implants or indwelling central catheters should also raise suspicion. An infection of ascending aortic graft is also a cause for concern^[96,121,123]. Prior valve replacement might lead to sooner detection of fungal IE^[106]. Third, immune compromised conditions^[71,83,107,120], such as post-splenectomy^[82] organ transplantation or malignancy^[45,85,100,112-114,117,122,125], or need for steroids for other reasons^[16,46,81,93], also offer an indication. However, some immunocompetent patients could suffer from fungal IE^[121] and risk factors may either be absent^[99,101] or restricted to an indwelling urinary catheter^[59,67]. Fourth, other clues can be IV drug use^[40,55,57,61,66,73,74,92], hemodialysis^[16,94], an earlier IE^[56,61], or extended treatment by antibiotics for other reasons^[54,70,86,101]. Last, a high index of suspicion for fungal IE should be maintained in patients with sepsis, negative blood culture before any antibiotic treatment, and known risk factors who do not respond

well to broad-spectrum antibiotics. In the absence of proof of fungal IE, antifungals are not considered till late in the course of disease progression. Rapid diagnosis and treatment for fungal IE are essential for good outcomes^[48,83,87,97,98]. Some fungi with low virulence can become widespread before causing symptoms^[121].

Blood cultures are a first pillar in the diagnosis of IE. At least three sets of blood cultures from separate venous puncture sites should be obtained^[127]. A negative culture can occur in over 50% of the cases^[43,48,58,74,80,126]. A negative culture can delay the diagnosis of IE with all its consequences. Reasons for this are prior antibiotic treatment, inadequate microbial techniques, fastidious organisms, and non-bacterial pathogens such as fungi. Culturing fungi requires mediums rich in carbohydrates, nitrogen, and a pH of 5-^[128], but there is no “one size fits all” scenario. After discussion with clinical laboratory experts, serial blood testing or incubation for several weeks can be considered necessary since these organisms are fastidious^[41,55,64,90,102,107,118]. So-called negative results should not be discarded^[86,96,102,104]. *Candida* is likely to be recovered as a causative agent in blood cultures, but a timely diagnosis of *Aspergillus* endocarditis remains elusive. When viable *Aspergillus* hyphae enter the bloodstream, they might be sequestered through endocytosis by endothelial cells, which could lead to endothelial cell injury and thrombosis. The only fungal elements that circulate in the bloodstream are non-viable, which explains the negative culture in many cases^[54,82-84,86]. *Aspergillus* endocarditis was diagnosed postmortem in approximately one-third of cases and was diagnosed preoperatively in less than half of patients^[97]. For *Histoplasma*, serologic examination can be performed^[106], which is useful in areas where this organism is endemic^[104,106,107]. Another difficulty arises when bacteria and fungi are identified simultaneously^[73,77,78,103] or cultures are positive for bacteria without demonstration of fungi, while the latter can be found in the excised valve, indicating a mixed infection. The presence of bacteremia should not reduce the suspicion of fungal IE, if other indicators such as large vegetation and emboli are present^[74]. Valve specimens, infected grafts^[96], abscesses^[88], and vegetations or emboli can be cultured and examined by histology and immunohistochemistry. Sometimes, identification can only be obtained postmortem^[48,120]. Cultures and histology of cutaneous nodules^[112,114], systemic ulcers, or abscesses^[55] can also give an early identification of the agent.

Microbiologic diagnosis of fungal IE

Other advanced diagnostic techniques include the detection of 1,3- β -D-glucan and mannan for *Candida*^[41,43,48,51,83,92,106] or for *Aspergillus*^[84,85,89,95,96,102] and other fungi^[52,107,118,121,123], but these methods are time-consuming^[107] and are not always easily available^[48]. Clearance of these antigens by neutrophil WBC can explain false negative results^[89,95]. This method could shorten the time to start an adequate antifungal treatment^[74,89]. For 1,3 β Dglucan, sensitivity is lower, but specificity remains high. For *Aspergillus*, the detection of galactomannan can be helpful. Molecular methods such as polymerase chain reaction (PCR) for the detection of fungal DNA can be used on blood or valve tissue in cases of negative blood cultures. The method is culture-independent and could give clarification in case of a contaminant. The results are rapidly obtained and large sequences are available in public databases. The method makes no distinction between viable and dead microorganisms, and false positive results can be obtained. Treatment success cannot be assessed with PCR^[127]. Pan-fungal PCR of blood, with real-time PCR targets for 18S-rRNA and 28S-rDNA^[41,43,71,83,92,112,121,125,126], has been used for *Aspergillus*^[81,94,95], *Mucormycosis*^[117], and *Sarocladium*^[120]. Metagenomic next-generation sequencing is culture-independent^[83,94,124,127,126] and allows the detection of fungi as causative agents of IE. It remains longer positive after the commencement of treatment. It is an efficient, rapid, and high-output technique that uses parallel and simultaneous sequencing of a multitude of gene fragments to determine the sequence of nucleic acid content from a sample. It can also identify fungi and antimicrobial resistance genes and responses to antimicrobial treatment. It allows the earlier institution of directed antifungal treatment with improved outcomes. The availability of this expensive and complex technique is limited, and if a specimen has to be sent out to a reference laboratory, results can be delayed. The method makes no distinction between viable and dead microorganisms. There is a contamination risk

with skin residing *Candida* and the method is not standardized^[127,128]. The matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) system is a complementary technique, which can analyze large proteins. The sample of fungi is crystallized within a matrix. By using a laser, the sample is ionized without being decomposed, and analyzed in a mass spectrometer. The data are analyzed by a specially designed software program and compared with a high number of pre-existent profiles. This method is cheap and quick and could become necessary in identifying unusual *Candida* species with different behavior^[52,66,68] or in cases for the distinction between a contaminant and rare pathogens^[111,113,115].

Echocardiographic evaluation of fungal IE

Medical imaging is a second pillar in the diagnosis of fungal IE. Transthoracic and transesophageal echography (TTE/TEE) are the first-line imaging modalities in the diagnosis of IE, the assessment of severity of disease, presence of paravalvular involvement, cavitory lesions, mural lesions, risk of embolism by sizing vegetation, and follow-up of treatment. If TTE is inconclusive and a degree of suspicion remains, TEE is indicated. Transesophageal echocardiography is more sensitive and specific compared to TTE, but serial examination is often required^[41], especially with a graft of the ascending aorta^[96], in cases with ICD^[103] or valve prosthesis^[110]. Repetition of these imaging modalities after 5 to 7 days has been^[1] recommended. Transesophageal echocardiography is also recommended when the patient is stable before switching from intravenous to oral antibiotic treatment (class IB), according to the latest ESC guidelines^[1].

However, even repeated TEE can remain negative for some time^[61]. Some echocardiographic features point to fungal IE, such as large vegetations^[48,57,64,68,78,84,99], obstruction of a valve prosthesis^[42,51,73,105,123], presence of fungal balls^[76,91], and mural, intracardiac and other non-valvular manifestations^[79,81,82,85,99,112,113,114,120,122]. TEE increases the diagnosis in TTE-negative patients, but this invasive procedure carries the risk of embolization^[38]. In cases with inconclusive imaging but a remaining degree of suspicion, PET/CT techniques can lead to improved detection of paravalvular lesions, especially in PVE. The radiolabeled glucose analog accumulates in activated inflammatory cells. Qualitative and quantitative analysis of the high-resolution images is possible, but proper patient preparation is needed with a high-fat but low-carbohydrate diet for at least 2 meals. PET/CT is of less value in patients with native valve IE because of low sensitivity^[38,129]. A PET/CT scan can be needed to detect fungal dissemination^[16,69,114,119] or local extension of the infection^[80,96].

Other imaging modalities in fungal IE

A cardiac CT can be needed to demonstrate the vegetation or filling defect^[123] or cardiac abscesses^[85]. Cardiac MRI can sometimes be necessary for the distinction between invasive aspergilloma and a tumor of the heart^[69,98,99]. CT/MRI of other regions is part of the work-up, especially in cases of stroke or infarctions and abscesses of other solid organs.

For *Candida* IE, Amphotericin with surgery should be the mainstay^[1,124], except for *C. lusitanae*, which has a rapid mutation rate^[66,67]. Liposomal Amphotericin formula is less nephrotoxic^[40,45,47,77,82,106,121]. A combination of antifungal therapy with flucytosine or an echinocandin appears to offer a survival benefit over single-agent treatment^[1,86]. Antifungal treatment reduces the risk of embolism within 2 weeks^[63]. *C. parapsilosis* poses specific problems: it is a nosocomial microorganism on the rise, with often a delayed identification in blood culture^[11], and a different type of biofilm compared to *C. albicans*. Biofilms are responsible for certain types of resistance^[109,110], but Amphotericin can still act on it^[49,52,82,92]. Antifungal susceptibility testing with minimal inhibitory concentrations with appropriate cut-off values is needed, especially when resistance is suspected^[65,72,92]. Echinocandins are also recommended against *Candida*^[16,49,56,76] because of their activity against fungal biofilms^[65,109]. Afterwards, a step down towards oral fluconazole is possible if the microbial agent is susceptible^[46,53]. However, fluconazole is fungistatic^[43,63] and is not a first

choice in *Candida* IE, also because of the increasing resistance of *C. parapsilosis*^[46,49,70].

Medical treatment of fungal IE in the acute phase

A liposomal amphotericin B preparation has been designed to reduce the nephrotoxicity, but it retains the antifungal activity. It has become a major component in the treatment of opportunistic fungal infections for over 20 years. The long half-life allows for intermittent administration. It was administered in patients with *C. parapsilosis*^[45,46,49-52] and other *Candida* species^[63,65,70] or a combination of *Candida* with a bacterial IE^[74,75,77], but not in patients with *C. albicans* infection. It has also been applied in several species of *Aspergillus*^[81,82,84-87,89,90,92,95-98], one patient with *Cryptococcus*^[100], all patients with *Histoplasma*^[104-107] and *Trichosporon*^[109-112], as well as in some other fungal species^[112,113,116,117,121-124]. Nevertheless, it was reduced in dosage in one of the cases^[124] and had to be discontinued in two other cases with renal failure^[116,121]. Voriconazole, fluconazole, caspofungin, micafungin were other often administered preparations. The regimen changed in some cases according to therapeutic failure and patterns of resistance. For *Aspergillus* IE, voriconazole seemed a first-choice drug^[81,82,85,87,89,95]. An echinocandin or Amphotericin could be associated^[1]. Amphotericin, however, could antagonize voriconazole^[81], and resistance of *Aspergillus* against voriconazole is rising^[87,94]. Voriconazole might be synergistic with caspofungin in some cases of *Aspergillus*, but this can be strain-dependent^[92]. Echinocandins, in combination with azoles, can be considered as salvage against *Aspergillus*^[81], but their value in association with Amphotericin is doubtful^[92]. Terbinafine has also been used against *Aspergillus*^[111]. For other types of fungal IE, such as *Cryptococcus*, *Mucormycosis*, *Histoplasma*, *Paecilomyces*, or *Trichosporon*, Amphotericin and some azoles have also been used^[101-103,107,109,117,121,122]. There are possible pharmacologic interactions in antifungal treatment. Fluconazole might interact with warfarin, which is sometimes given to treat emboli^[54]. In case of mixed bacterial/fungal infection or in patients needing immune suppression, interactions with antibiotics should also be anticipated^[45,84,117]. There could also be an antagonism between Amphotericin and azoles, but this complex issue is not established and is dose-dependent^[86].

Surgical approach for fungal IE

Surgery is needed in most cases of fungal IE, especially in cases where antifungal medication penetrates biofilms poorly^[67], for abscesses debridement^[65] or to prevent embolism^[57]. Determining the optimal timing of surgery following cerebral events with hemorrhagic transformation poses challenges^[41,84,87,93,110]. Early surgical intervention should be considered, particularly for patients with bulky and friable vegetation and biofilms on implanted materials^[38,41,43,46,47,49,51,52,70,116], fungal PVE, and risk of recurrence, especially in the case of *Aspergillus*^[82,85,86,87,88]. Without surgery and proper antifungal treatment, the prognosis of *Aspergillus*^[85,88,104] or histoplasmosis and other fungal IE is dismal^[43,106]. In the case of fungal IE, all central catheters, pacemakers, and internal defibrillators should be removed as early as possible^[58,72,78,89,103].

The initial management for fungal IE should be followed by long-term treatment. Regimens recommended for PVE by *Candida* have an induction phase of 6 weeks with amphotericin or caspofungin, followed by lifelong suppressive maintenance therapy with high-dose fluconazole. Fluconazole for *Candida* and voriconazole for *Aspergillus* are recommended to prevent relapse^[46,64,66,85]. Sometimes, this is for life, after fungal PVE^[47,58,70,73,119], or when surgery is indicated but cannot be performed^[43,76,47,70,111]. However, this issue is still debated^[41,43,74,88,92,89,110,116].

Outcome of fungal IE: mortality

In spite of aggressive treatment, fungal IE had an early mortality of 40% to 50%^[11,41,44,46,49,57,64,69,76,78] and 1-year mortality was up to 59%^[57]. Prosthetic valve endocarditis by *C. parapsilosis* has a much higher complication (including emboli) and mortality rate compared to bacterial PVE^[38]. Need for admission to the ICU, organ failure, and the presence of a central venous catheter were risk factors. Removal of these catheters had a

positive effect on outcomes at any time, while the inability to remove the catheter increased mortality^[130]. Other factors for worse outcomes were large vegetation with a risk for embolization or an immune compromised state^[52,126]. In the latter patients, it seemed reasonable to start an empirical antifungal treatment when fever persists and antibiotics are ineffective^[126]. An older meta-analysis^[131] showed that antifungal monotherapy without surgery had a poor prognosis. Brain abscesses have an estimated mortality of 85%-100%^[41]. Consultation with an infection specialist from the Endocarditis Team is recommended^[1,45,46,65,124] to optimize management and prevent resistance. Times to evaluation could become shorter and more adequate. A survey revealed that the endocarditis team improved communication between specialties by preventing fragmentation of information, influencing diagnostic evaluation, reducing management errors, and increasing access to surgery, thereby decreasing in-hospital mortality^[132]

LIMITATIONS

This analysis has the limitations of any retrospective analysis of heterogeneous, observational studies and case reports. Patient series rarely elaborate on the fungus species. The presentation of the cases is not standardized. The only common factor is the diagnosis of definitive fungal IE. A distinction between right-sided and left-sided IE has not been made in this analysis. The uncontrolled variables are patient characteristics and medical and surgical management. There is a risk of underreporting complications. Above all, the delay in treatment has hardly been investigated. This makes it impossible to draw firm recommendations from the included cases. There is also potential for publication bias towards cases with rare fungi, or a favorable outcome, or a certain treatment modality. There is little mention in the individual reports of long-term suppressive antifungal therapy, so it is impossible to analyze how that may have impacted treatment outcomes. A long-term follow-up remains significantly incomplete.

CONCLUSION AND FUTURE DIRECTION

Fungal endocarditis remains a rare but highly lethal condition. *Candida* and *Aspergillus* are still the dominant microorganisms. Risk factors are prior implanted cardiac devices and valves, IV drug use, and immune suppression. Clinical symptoms and signs are unspecific, but imaging data such as large vegetation and non-valvular manifestation are suggestive of fungal IE. Additional imaging for locale extension and embolic complications is indispensable. Early diagnosis and prompt surgical intervention coupled with optimal antifungal therapy under the guidance of a specialized endocarditis team are the only options to reduce the extremely high mortality and morbidity. Due to the low incidence of fungal IE, most information available comes from case reports or small series, as currently included. Therefore, one can expect a lack of uniformity in the approach to this condition. Questions still unresolved are (1) what is the effect of a delay of diagnosis on outcome; (2) how can this delay be reduced effectively; (3) what is the most effective long-term strategy to reduce relapse; and (4) is the individual outcome more determined by the virulence of the fungi or by the pre-existing condition of the patient? To address these questions, a dedicated IE team has been recommended in the most recent ESC guidelines^[1] for the treatment of fungal IE. Moreover, a multicenter international registry with a standardized diagnostic and therapeutic approach and recording of the treatment outcome is still lacking. The establishment of such a registry could be helpful in improving the results. The factors which need to be included are listed as a [Supplementary Material](#).

DECLARATIONS

Authors' contributions

The author contributed solely to the article.

Availability of data and materials

Not applicable.

Financial support and sponsorship

None.

Conflicts of interest

The author declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2024.

REFERENCES

1. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM). *Eur Heart J* 2023;44:3948-4042. DOI
2. Mistiaen WP, Gebruers N. How to manage patients in whom malignancy and infective endocarditis are associated: a review. *Scand Cardiovasc J* 2020;54:70-6. DOI PubMed
3. Meshaal MS, Labib D, Said K, et al. Aspergillus endocarditis: diagnostic criteria and predictors of outcome, a retrospective cohort study. *PLoS One* 2018;13:e0201459. DOI PubMed PMC
4. Cresalia NM, Owens ST, Stillwell TL, et al. Not just vegetations: focal myocardial changes in patients with fungal infections. *Cardiol Young* 2021;31:199-204. DOI
5. Lefort A, Chartier L, Sendid B, et al. Diagnosis, management and outcome of Candida endocarditis. *Clin Microbiol Infect* 2012;18:E99-109. DOI
6. McCormack J, Pollard J. Aspergillus endocarditis 2003-2009. *Med Mycol* 2011;49 Suppl 1:S30-4. DOI PubMed
7. Ramos JM, Cuenca-Estrella M, Gutierrez F, Elia M, Rodriguez-Tudela JL. Clinical case of endocarditis due to trichosporon inkin and antifungal susceptibility profile of the organism. *J Clin Microbiol* 2004;42:2341-4. DOI PubMed PMC
8. Jinno S, Gripshover BM, Lemonovich TL, Anderson JM, Jacobs MR. Histoplasma capsulatum prosthetic valve endocarditis with negative fungal blood cultures and negative histoplasma antigen assay in an immunocompetent patient. *J Clin Microbiol* 2010;48:4664-6. DOI PubMed PMC
9. Roy M, Ahmad S, Roy AK. Cryptococcus neoformans infective endocarditis of native valves in an immunocompetent host. *ID Cases* 2018;12:66-70. DOI PubMed PMC
10. Acibuca A, Yilmaz M, Okar S, et al. An epidemiological study to define the recent clinical characteristics and outcomes of infective endocarditis in southern Turkey. *Cardiovasc J Afr* 2021;32:188-92. DOI PubMed PMC
11. Jerónimo A, Olmos C, Vilacosta I, et al. Contemporary comparison of infective endocarditis caused by Candida albicans and Candida parapsilosis: a cohort study. *Eur J Clin Microbiol Infect Dis* 2022;41:981-7. DOI
12. Cahill TJ, Jewell PD, Denne L, et al. Contemporary epidemiology of infective endocarditis in patients with congenital heart disease: a UK prospective study. *Am Heart J* 2019;215:70-7. DOI
13. Polewczyk A, Jacheć W, Segreti L, Bongiorno MG, Kutarski A. Influence of the type of pathogen on the clinical course of infectious complications related to cardiac implantable electronic devices. *Sci Rep* 2021;11:14864. DOI PubMed PMC
14. Ragnarsson S, Salto-Alejandre S, Ström A, Olaison L, Rasmussen M. Surgery is underused in elderly patients with left-sided infective endocarditis: a nationwide registry study. *J Am Heart Assoc* 2021;10:e020221. DOI PubMed PMC
15. Rodger L, Shah M, Shojaei E, Hosseini S, Koivu S, Silverman M. Recurrent endocarditis in persons who inject drugs. *Open Forum Infect Dis* 2019;6:ofz396. DOI PubMed PMC
16. Sousa C, Nogueira P, Pinto FJ. Insight into the epidemiology of infective endocarditis in Portugal: a contemporary nationwide study from 2010 to 2018. *BMC Cardiovasc Disord* 2021;21:138. DOI PubMed PMC
17. Berisha B, Ragnarsson S, Olaison L, Rasmussen M. Microbiological etiology in prosthetic valve endocarditis: a nationwide registry study. *J Intern Med* 2022;292:428-37. DOI PubMed PMC
18. Fosbøl EL, Park LP, Chu VH, et al. The association between vegetation size and surgical treatment on 6-month mortality in left-sided infective endocarditis. *Eur Heart J* 2019;40:2243-51. DOI

19. Vallejo Camazón N, Cediel G, Núñez Aragón R, et al. Short- and long-term mortality in patients with left-sided infective endocarditis not undergoing surgery despite indication. *Rev Esp Cardiol* 2020;73:734-40. DOI
20. Elad B, Perl L, Hamdan A, et al. The clinical value of the endocarditis team: insights from before and after guidelines implementation strategy. *Infection* 2022;50:57-64. DOI
21. Jia YX, Li Y, Meng X, et al. Clinical analysis of 161 cases of surgical treatment of infective endocarditis. *Surg Infect* 2019;20:637-42. DOI
22. Gutierrez-Villanueva A, Muñoz P, Delgado-Montero A, et al. Mural endocarditis: the GAMES registry series and review of the literature. *Infect Dis Ther* 2021;10:2749-64. DOI PubMed PMC
23. Salsano A, Giacobbe DR, Del Puente F, et al. Culture-negative infective endocarditis (CNIE): impact on postoperative mortality. *Open Med* 2020;15:571-9. DOI PubMed PMC
24. Sunder S, Grammatico-Guillon L, Lemaigen A, et al. Incidence, characteristics, and mortality of infective endocarditis in France in 2011. *PLoS One* 2019;14:e0223857. DOI PubMed PMC
25. Tahon J, Geselle PJ, Vandenberg B, et al. Long-term follow-up of patients with infective endocarditis in a tertiary referral center. *Int J Cardiol* 2021;331:176-82. DOI
26. Martínez-Sellés M, Tattevin P, Valerio-Minero M, et al. Infective endocarditis in patients with heart transplantation. *Int J Cardiol* 2021;328:158-62. DOI
27. Mir T, Uddin M, Qureshi WT, Regmi N, Tleyjeh IM, Saydain G. Predictors of complications secondary to infective endocarditis and their associated outcomes: a large cohort study from the national emergency database (2016-2018). *Infect Dis Ther* 2022;11:305-21. DOI
28. Okura T, Iwata K, Koyama T, et al. Impact of infectious disease consultation on management and outcomes of infective endocarditis. *Ann Thorac Surg* 2021;112:1228-34. DOI
29. Pasupula DK, Bhat AG, Siddappa Malleshappa SK, et al. Trends and predictors of 30-day readmission among patients hospitalized with infective endocarditis in the United States. *Cureus* 2019;11:e4962. DOI PubMed PMC
30. Geirsson A, Schranz A, Jawitz O, et al. The evolving burden of drug use associated infective endocarditis in the United States. *Ann Thorac Surg* 2020;110:1185-92. DOI PubMed PMC
31. Guo M, St Pierre E, Clemence J Jr, et al. Impact of chronic renal failure on surgical outcomes in patients with infective endocarditis. *Ann Thorac Surg* 2021;111:828-35. DOI PubMed PMC
32. Pyo WK, Kim HJ, Kim JB, et al. Comparative surgical outcomes of prosthetic and native valve endocarditis. *Korean Circ J* 2021;51:504-14. DOI PubMed PMC
33. Houhamdi-Hammou L, Benito Y, Boibieux A, et al. *Malassezia restricta*: an underdiagnosed causative agent of blood culture-negative infective endocarditis. *Clin Infect Dis* 2021;73:1223-30. DOI
34. Ramanathan A, Witten JC, Gordon SM, Griffin BP, Pettersson GB, Shrestha NK. Factors associated with local invasion in infective endocarditis: a nested case-control study. *Clin Microbiol Infect* 2021;27:1011-4. DOI PubMed
35. Chen Y, Ye LJ, Wu Y, et al. Neutrophil-lymphocyte ratio in predicting infective endocarditis: a case-control retrospective study. *Med Inflamm* 2020;2020:8586418. DOI PubMed PMC
36. Chuang S, Shrestha NK, Brizendine KD. Matched retrospective study of infective endocarditis among solid organ transplant recipients compared to non-transplant: Seven-year experience in a US Referral Center. *Transpl Infect Dis* 2020;22:e13368. DOI
37. Gröning M, Tahri NB, Søndergaard L, Helvind M, Ersbøll MK, Ørbæk Andersen H. Infective endocarditis in right ventricular outflow tract conduits: a register-based comparison of homografts, Contegra grafts and Melody transcatheter valves. *Eur J Cardiothorac Surg* 2019;56:87-93. DOI PubMed
38. Ponnambath DK, Gopalakrishnan A, Pillai VV, Kaviyil JE, Raja K. Clinical profile of prosthetic valve endocarditis due to *Candida parapsilosis*: an 11-year retrospective observational study from a quaternary cardiac referral institute in India. *Indian J Crit Care Med* 2021;25:860-5. DOI PubMed PMC
39. Cao GF, Liu W, Cao L, Wang Y. Stroke in patients with prosthetic valve endocarditis: single-center cohort study in China. *Herz* 2020;45:72-7. DOI
40. Aboud H, Bejjani H, Clapp WL, Koratala A. Pauci-immune proliferative glomerulonephritis and fungal endocarditis: more than a mere coincidence? *BMJ Case Rep* 2019;12:e229059. DOI PubMed PMC
41. Beires F, Rocha R, Mata D, Ramos S, Moreno N. Fungal endocarditis: a rare case of multiple arterial embolization. *Cureus* 2023;15:e33312. DOI PubMed PMC
42. Carrel T, Eberle B. *Candida* endocarditis after TAVR. *N Engl J Med* 2019;380:e1. DOI PubMed
43. da Silva F, Cardoso FS, Esteves A, Carvalho J, Maia R. Relapsing *Candida parapsilosis* endocarditis with septic embolization: a case report. *Cureus* 2021;13:e13159. DOI PubMed PMC
44. de Santis A, Gilberto GM, Mangini S, et al. A medical epopee: recurrent fungal endocarditis, heart transplantation and chylopericardium. *BMC Cardiovasc Disord* 2020;20:469. DOI PubMed PMC
45. Hebert J, Barr E, Magee C. Pacemaker-related *Candida parapsilosis* fungaemia in an immunosuppressed renal transplant recipient. *BMJ Case Rep* 2021;14:e242917. DOI PubMed PMC
46. Ioannou P, Volosyraki M, Mavrikaki V, et al. *Candida parapsilosis* endocarditis. Report of cases and review of the literature. *GERMS* 2020;10:254-9. DOI PubMed PMC
47. Khadilkar AC, Diaz Vera J, Enciso J, Hernandez Burgos P. Cardiac imaging and management of prosthetic valve candida parapsilosis

- endocarditis. *Cureus* 2021;13:e16082. DOI PubMed PMC
48. Monteiro M, Sismeiro R, Negrão C, Jonet M, Simoa G. Fungal endocarditis: a case report. *Cureus* 2021;13:e20156. DOI PubMed PMC
49. Morioka H, Tokuda Y, Oshima H, et al. Fungal endocarditis after transcatheter aortic valve replacement (TAVR): case report and review of literature. *J Infect Chemother* 2019;25:215-7. DOI
50. Romeo MG, Comentale G, Cirillo V, Pilato E. Sars-Cov-2 infection as a possible risk factor for prosthesis endocarditis: a challenging redo-Bentall for subvalvular abscess. *J Card Surg* 2022;37:2845-8. DOI PubMed PMC
51. Sakakibara K, Nakajima H. A case of *Candida parapsilosis* bioprosthetic valve endocarditis. *Clin Case Rep* 2023;11:e6950. DOI PubMed PMC
52. Sharma S, Samantaray S, Kumar D, et al. Prosthetic valve endocarditis due to *Candida parapsilosis* - a rare case report. *Access Microbiol* 2023;5:000462.v4. DOI PubMed PMC
53. Tan W, Dora A, Lluri G, Aboulhosn J. *Candida parapsilosis* endocarditis following transcatheter pulmonary valve implantation. *World J Pediatr Congenit Heart Surg* 2020;11:112-3. DOI PubMed
54. Zhu X, Cao S, Xia M, Ding C, Wang R. Fungal endocarditis with heart valve replacement and atrial fibrillation posing a treatment challenge: a case report. *Medicine* 2020;99:e22487. DOI PubMed PMC
55. Dixit N, Escobedo ES, Ebrahimi R. Use of the 1,3- β -D-glucan assay for the early detection of fungal endocarditis in a 45-year-old man. *Am J Case Rep* 2020;21:e926206. DOI PubMed PMC
56. Carneiro H, Rasalingam R. Fungal prosthetic aortic valve endocarditis and endarteritis: an unusual cause of aortic root vegetations. *Echocardiography* 2019;36:401-5. DOI PubMed
57. Piątek Ł, Piątek K, Kurzawski J, et al. A rare case of a native aortic valve fungal endocarditis in a young woman. *Med Stud* 2022;38:245-8. DOI
58. Rauf H, Ullah W, Roomi S, et al. An unusual case of fungal ball on implantable cardioverter defibrillator wire and literature review. *J Community Hosp Intern Med Perspect* 2020;10:340-2. DOI PubMed PMC
59. Sheikh T, Tomcho JC, Awad MT, Zaidi SR. *Candida albicans* endocarditis involving a normal native aortic valve in an immunocompetent patient. *BMJ Case Rep* 2020;13:e236902. DOI PubMed PMC
60. Sousa M, Martins J, Barreto S, et al. A rare complication of a hemodialysis tunneled catheter: case report of a superior vena cava and right atrium *Candida* endocarditis. *ID Cases* 2020;20:e00768. DOI PubMed PMC
61. Walker M, Levitt MR, Gibbons EF, Horne DJ, Corcorran MA. Clot analysis in acute ischemic stroke, a case of fungal endocarditis. *Stroke* 2019;50:e106-9. DOI PubMed
62. Mishra AK, Sahu KK, Lal A, Sujata M. Systemic embolization following fungal infective endocarditis. *QJM* 2020;113:233-5. DOI PubMed
63. Bauer BK, Schulze AB, Löher A, Reinke F, Eckardt L. *Candida tropicalis* defibrillator endocarditis: a case report and review of current literature. *Med Mycol Case Rep* 2019;25:1-9. DOI PubMed PMC
64. Kozłowska A, Sołtowska A, Kwinecki P, Augustyn C, Mieczynski M, Jaroch J. An enormous fungal vegetation of the tricuspid valve: a cardiac surgical repair with a CorMatrix valve. *Kardiol Pol* 2019;77:978-9. DOI PubMed
65. Agnelli C, Guinea J, Valerio M, Escribano P, Bouza E, Muñoz P. Infectious endocarditis caused by *Candida glabrata*: evidence of *in vivo* development of echinocandin resistance. *Rev Esp Quimioter* 2019;32:395-7. PubMed
66. Rahmati E, Correa AJ, She RC. A budding case of infectious endocarditis: *Candida lusitanae*. *ID Cases* 2020;19:e00679. DOI
67. Raja A, Park J. Disseminated *Candida lusitanae*: nosocomial acquisition secondary to an indwelling urinary catheter. *Case Rep Infect Dis* 2021;2021:6632730. DOI PubMed PMC
68. Castro LÁ, Álvarez MI, Rojas F, Giusiano G, Martínez E. *Candida auris* infection in the central catheter of a patient without sepsis symptoms. *Colomb Med* 2019;50:293-8. DOI PubMed PMC
69. Girod BJ, Guja KE, Davidzon G, et al. Fungal endocarditis resembling primary cardiac malignancy in a patient with B-cell ALL with culture confirmation. *Radiol Case Rep* 2020;15:117-9. DOI PubMed PMC
70. Sanku K, Youssef D. Native valve *Candida metapsilosis* endocarditis following a ruptured appendix: a case report. *Cureus* 2022;14:e21178. DOI PubMed PMC
71. Sgreccia A, Carità G, Coskun O, et al. Acute ischemic stroke treated with mechanical thrombectomy and fungal endocarditis: A case report and systematic review of the literature. *J Neuroradiol* 2020;47:386-92. DOI
72. Merza N, Lung J, Bainum TB, et al. First reported case of *Candida dubliniensis* endocarditis related to implantable cardioverter-defibrillator. *Case Rep Cardiol* 2020;2020:6032873. DOI PubMed PMC
73. Laporte C, Schulte TE, Markin NW. Perioperative management of recurrent fungal tricuspid endocarditis in a young patient abusing intravenous drugs. *CASE* 2019;3:231-4. DOI PubMed PMC
74. Kaur M, Virdi P, Kaur R, Abidov A, Levine DL. Polymicrobial *Pseudomonas* plus *Candida parapsilosis* endocarditis in an injection drug user: considerations for diagnosis and management. *Cureus* 2021;13:e13507. DOI PubMed PMC
75. Agrawal DP, Joshi AS, Nm S. The curious case of coronary cameral fistula with infective endocarditis: a rare harbinger of a common clinical entity. *Turk Gogus Kalp Damar Cerrahisi Derg* 2021;29:248-51. DOI PubMed PMC
76. Jafry AH, Ijaz SH, Mazhar M, Shahnawaz A, Yousif A. Not "Much Room" in the heart: a rare case of a massive intracardiac *Candida* mass. *Case Rep Infect Dis* 2021;2021:9216825. DOI PubMed PMC
77. Kollu VS, Kalagara PK, Islam S, Gupte A. A report of *Candida blankii* fungemia and possible endocarditis in an immunocompetent

- individual and the review of literature. *Cureus* 2021;13:e14945. DOI PubMed PMC
78. Labchuk A, Hamwi M, Han A, Khan M, Stone A. Fungal endocarditis with severe vegetations of the aortic valve and septic emboli secondary to total parenteral nutrition. *Cureus* 2022;14:e32357. DOI PubMed PMC
 79. Morton K, Heindl B, McElwee SK, Litovsky S, Ahmed MI, Clarkson S. Percutaneous debulking of tricuspid valve endocarditis in severe COVID-19 pneumonia after prolonged venovenous extracorporeal membrane oxygenation with right-ventricular support: a case series. *Eur Heart J Case Rep* 2023;7:ytac409. DOI PubMed PMC
 80. Wong MKH, Rocha BA, Au TWK. Intracardiac foreign body: a rare cause of recurrent fungemia. *J Card Surg* 2020;35:2844-6. DOI PubMed
 81. Chevalier K, Barde F, Benhamida S, et al. Invasive aspergillosis and endocarditis Aspergillose invasive et endocardite. *Revue Med Int* 2021;42:678-85. DOI
 82. Aggarwal A, Hogan K, Paez A. Aspergillus fumigatus endocarditis in a splenectomized patient with no risk factors. *IDCases* 2020;19:e00694. DOI PubMed PMC
 83. Aldosari MA, Alghamdi MH, Alhamdan AA, Alamri MM, Ahmed AM, Aziz MS. Native valve fungal endocarditis caused by Aspergillus fumigatus: management dilemma. *Oxf Med Case Reports* 2020;2020:omz147. DOI PubMed PMC
 84. Hatlen TJ, Filler SG, Bayer A, Shah S, Shodhan S, Van TT. Aspergillus endocarditis diagnosed by fungemia plus serum antigen testing. *Med Mycol Case Rep* 2019;23:1-3. DOI PubMed PMC
 85. Hiroshima Y, Kurumisawa S, Aizawa K, Fukushima N, Kawahito K. Successful treatment of Aspergillus mural endocarditis in malignant lymphoma using a combined antifungal and surgical approach: a case report. *Surg Case Rep* 2020;6:128. DOI PubMed PMC
 86. Lennard K, Bannan A, Grant P, Post J. Potential benefit of combination antifungal therapy in Aspergillus endocarditis. *BMJ Case Rep* 2020;13:e234008. DOI PubMed PMC
 87. Manja K, Matjaz H, Jus K, Katja AJ, Marko S, Mateja L. Native valve Aspergillus fumigatus endocarditis in a patient with autoimmune hepatitis on low dose systemic corticosteroids: a case report. *ID Cases* 2023;31:e01728. DOI PubMed PMC
 88. Nanditha S, Iyer GKT, Raghu B, Prashanth YM, Yadav V. An unusual case of Aspergillus endocarditis of native aortic valve following ECMO. *Indian J Thorac Cardiovasc Surg* 2020;36:420-2. DOI PubMed PMC
 89. Ray U, Dutta S, Khan A. A case of pacemaker associated Aspergillus fumigatus endocarditis. *J Glob Infect Dis* 2022;14:38-40. DOI PubMed PMC
 90. Sloane KL, Raymond SB, Rabinov JD, Singhal AB. Mechanical thrombectomy in stroke from infective endocarditis: case report and review. *J Stroke Cerebrovasc Dis* 2020;29:104501. DOI PubMed
 91. Al-Mashdali AF, Alamin MA, Kanaan AM, Alkhulaifi A, Al Kindi DI. Fatal native aortic valve fungal endocarditis caused by Aspergillus flavus: a case report. *ID Cases* 2021;26:e01310. DOI PubMed PMC
 92. Born T, Aruanno M, Kampouri E, et al. Aspergillus tubingensis Endocarditis: a case report and review of the literature. *Mycopathologia* 2022;187:249-58. DOI PubMed PMC
 93. Carvalho JA, Boavida L, Amorim Ferreira I, Grima B, Delgado Alves J. Native valve aspergillus endocarditis in a non-neutropenic immunocompromised patient on anti-TNF α blockers therapy. *Cureus* 2021;13:e20629. DOI PubMed PMC
 94. Dai T, Hu Q, Xie Z, Li C. Case report: infective endocarditis caused by Aspergillus flavus in a hemodialysis patient. *Front Med* 2021;8:655640. DOI PubMed PMC
 95. Jalalian R, Shokohi T, Mirzakhani R, et al. Fatal prosthetic valve endocarditis due to Aspergillus flavus in a diabetic patient. *Infect Drug Resist* 2020;13:2245-50. DOI PubMed PMC
 96. Marro M, Atzeni F, La Torre MW, et al. Insidious postoperative Aspergillus niger graft aortitis. *ID Cases* 2020;21:e00823. DOI PubMed PMC
 97. Patil P, Nambi PS, Kumar P, Salgunan N, Reddy H. Infective endocarditis of native valves due to aspergillus in an immunocompetent host: a rare presentation. *J Clin Diagnostic Res* 2022;16:OD01-3. DOI
 98. Pervaiz AM, Bangash SA, Akhtar R, Wahab Z, Bangash H. A rare presentation of cardiac aspergilloma in an immunocompetent host: case report and literature review. *Cureus* 2019;11:e4784. DOI PubMed PMC
 99. Tabandeh M, Bahramali E, Savand Roomi Z, Salari S, Radpey M, Shamsolvaezin N. Intra-cardiac aspergilloma in a normally structured heart: a case report. *J Cardiol Cases* 2020;21:165-8. DOI PubMed PMC
 100. Fountain JH, Rajagopalan KN, Carroll M, et al. Cryptococcus neoformans infective endocarditis after lung transplantation: a case report and review of the literature. *Infect Dis Clin Pract* 2021;29:e457-61. DOI PubMed PMC
 101. Li Y, He S, Lu Z, et al. Cryptococcal endocarditis of native valves without immunodeficiency or drug abuse: a case report. *J Int Med Res* 2020;48:300060520970763. DOI PubMed PMC
 102. McGuire CN, Walter DJ. Cryptococcus neoformans endocarditis in an immunocompetent patient a case report. *BMC Cardiovasc Disord* 2022;22:565. DOI PubMed PMC
 103. Nakajima T, Oba Y, Takashima J, et al. Cryptococcus endocarditis: a case report and review of the literature. *J Infect Chemother* 2019;25:901-5. DOI
 104. Adigun RO, Baddour LM, Geske JB. A case report of Histoplasma capsulatum prosthetic valve endocarditis: an extremely rare presentation with characteristic findings. *Eur Heart J Case Rep* 2019;3:ytz127. DOI PubMed PMC
 105. Amnuay K, Sirinawin C, Theerasuwipakorn N, Chattranukulchai P, Suankratay C. Native valve infective endocarditis caused by histoplasma capsulatum in an immunocompetent host: the first case in asia and literature review in asia and australia. *Case Rep Infect*

- Dis* 2021;2021:9981286. DOI PubMed PMC
106. Boyanton BL Jr, Boamah H, Lauter CB. Native vs prosthetic valve histoplasma capsulatum infective endocarditis: a case report and systemic literature review comparing patient presentation, treatment modalities, clinical outcomes, and diagnostic laboratory testing. *Open Forum Infect Dis* 2021;8:ofab360. DOI PubMed PMC
 107. Manning EM, Zorach B, Kumar A. Rare case of Histoplasma capsulatum endocarditis in a patient with a prosthetic valve. *Eur Heart J Case Rep* 2022;6:ytac086. DOI PubMed PMC
 108. Couto R, Couto G, Abrahão I, Compagnoni I, Carnio T, Tolentino J. Endocarditis due to Trichosporon beigelii 11 years after mitral valve replacement. *Rev Port Cardiol* 2021;40:305.e1-3. DOI PubMed
 109. Oh TH, Shin SU, Kim SS, et al. Prosthetic valve endocarditis by Trichosporon mucoides: a case report and review of literature. *Medicine* 2020;99:e22584. DOI PubMed PMC
 110. Paniagua LM, Sudhakar D, Perez LE, et al. Prosthetic valve endocarditis from trichosporon asahii in an immunocompetent patient. *JACC Case Rep* 2020;2:693-6. DOI PubMed PMC
 111. Tse C, Boodman C, Wuerz T. Trichosporon mucoides prosthetic valve endocarditis managed with antifungal suppression therapy. *Med Mycol Case Rep* 2022;36:10-2. DOI PubMed PMC
 112. Hannemann M, Wilmes D, Dombrowski F, et al. Splenic rupture and fungal endocarditis in a pediatric patient with invasive fusariosis after allogeneic hematopoietic stem cell transplantation for aplastic anemia: a case report. *Front Pediatr* 2022;10:1060663. DOI PubMed PMC
 113. Peinado-Acevedo JS, Ramírez-Sánchez IC. Endocarditis by fusarium keratoplasticum. *Mycopathologia* 2021;186:131-3. DOI PubMed
 114. Bourlond B, Cipriano A, Regamey J, et al. Case report: disseminated scedosporium apiospermum infection with invasive right atrial mass in a heart transplant patient. *Front Cardiovasc Med* 2022;9:1045353. DOI PubMed PMC
 115. Demir T, Baris A, Sigirci S, Sigirci BB, Tanriverdi ES, Koramaz I. Infective endocarditis caused by Chaetomium globosum. *Cardiovasc Pathol* 2023;62:107467. DOI PubMed
 116. Granok AB. Successful treatment of malassezia furfur endocarditis. *Open Forum Infect Dis* 2020;7:ofaa029. DOI PubMed PMC
 117. Hagemann JB, Furitsch M, Wais V, et al. First case of fatal Rhizomucor miehei endocarditis in an immunocompromised patient. *Diagn Microbiol Infect Dis* 2020;98:115106. DOI
 118. Hiruta R, Sato N, Ishikawa T, et al. Mechanical thrombectomy for acute ischemic stroke caused by prosthetic aortic valve endocarditis due to exophiala dermatitidis infection: a case report. *NMC Case Rep J* 2021;8:835-40. DOI PubMed PMC
 119. Khalique Z, Hatipoğlu S, Rosendahl U, Mohiaddin R. Unusual complicated fungal endocarditis in a patient with vascular ehlers-danlos syndrome. *Ann Thorac Surg* 2019;107:e269-71. DOI
 120. Kitamura H, Kubota Y, Tomimasu R, et al. Non-valvular infective endocarditis caused by sarocladium kiliense in an immunocompromised patient with aplastic anemia. *Intern Med* 2022;61:1279-83. DOI PubMed PMC
 121. Lazarus JE, Branda JA, Gandhi RG, Barshak MB, Zachary KC, Barczak AK. Disseminated intravascular infection caused by paecilomyces variotii: case report and review of the literature. *Open Forum Infect Dis* 2020;7:ofaa166. DOI PubMed PMC
 122. Mita A, Hirano S, Uehara T, et al. Fatal disseminated mucormycosis due to Cunninghamella bertholletiae infection after ABO-incompatible living donor liver transplantation: a case report. *Surg Case Rep* 2022;8:164. DOI PubMed PMC
 123. Seitler S, Bruce C, Rosendahl U, et al. Don't stop beleafing: a unique case of fungal infective endocarditis. *JACC Case Rep* 2021;3:672-7. DOI PubMed PMC
 124. Shephard EA, Sapozhnikov J, Beckerman Z, Murphey DK. Early diagnosis with sequencing and successful treatment of Bipolaris prosthetic valve endocarditis. *Med Mycol Case Rep* 2022;36:13-5. DOI PubMed PMC
 125. Tien JZ, Chou CH, Ho MW, Chen TT. Lethal mushroom: volvariella volvacea infective endocarditis in a patient after allogeneic peripheral blood stem cell transplantation. *J Formos Med Assoc* 2020;119:664-6. DOI
 126. Ammannaya GKK, Sripad N. Fungal endocarditis: what do we know in 2019? *Kardiol Pol* 2019;77:670-3. DOI PubMed
 127. Haddad SF, DeSimone DC, Chesdachai S, Gerberi DJ, Baddour LM. Utility of metagenomic next-generation sequencing in infective endocarditis: a systematic review. *Antibiotics* 2022;11:1798. DOI PubMed PMC
 128. Basu S, Bose C, Ojha N, et al. Evolution of bacterial and fungal growth media. *Bioinformation* 2015;11:182-4. DOI PubMed PMC
 129. Mistiaen W. Scintigraphic Evaluation of endocarditis. *Int J Cardiol Lipidol Res* 2018;V5:8-13. DOI
 130. Nakamura T, Narui R, Holmes B, et al. Candidemia in patients with cardiovascular implantable electronic devices. *J Interv Card Electrophysiol* 2021;60:69-75. DOI
 131. Steinbach WJ, Perfect JR, Cabell CH, et al. A meta-analysis of medical versus surgical therapy for Candida endocarditis. *J Infect* 2005;51:230-47. DOI
 132. El-Dalati S, Khurana I, Soper N, et al. Physician perceptions of a multidisciplinary endocarditis team. *Eur J Clin Microbiol Infect Dis* 2020;39:735-9. DOI